Shenzhen Tyercan Biopharm Completes Tens of Millions RMB Angel Financing to Advance PDC Drug Pipeline

VCBeat has learned that Shenzhen Tyercan Biopharm has recently completed an angel financing round worth tens of millions of RMB. The round was led by Xiantong Capital, a well-known professional investment institution in the biopharmaceutical sector, with participation from Shiyao Xiantong, Xinghongsheng, Hongya Zhiru, Bangqin Xingrui, and Zhirong Chuangye. The funds raised will be used to accelerate preclinical research and Investigational New Drug (IND) application for its next-generation targeted anti-cancer drug candidate, Tye-1001, strengthen team building, further enrich the company’s pipeline of targeted anti-cancer and immunosuppressive drugs, and promote the development of its “peptide-targeted innovative technology platform.”

Tyercan Pharma is a national high-tech enterprise founded by a team of overseas-returned PhDs and supported by Shenzhen’s High-Level Innovation and Entrepreneurship Team Program. The company focuses on the cutting-edge field of drug development—specifically Peptide-Drug Conjugates (PDCs) and peptide targeting technologies—to develop original, independently owned intellectual property rights-based peptide-targeted anticancer agents and targeted immunosuppressive drugs. Committed to the research and development of Class I innovative drugs, Tyercan aims to advance multiple product candidates into preclinical studies, Investigational New Drug (IND) applications, and subsequent Phase I/II/III clinical trials, with the goal of providing patients with more effective and superior targeted therapeutic options as soon as possible.

Regarding this lead investment, Dang Ting, Investment Director at Xiantong Capital, stated, “Telikang leverages its peptide-drug conjugate (PDC) platform technology to develop a variety of innovative targeted therapies. Compared with antibody-drug conjugates (ADCs), PDCs offer distinct advantages and can address certain unmet clinical needs with their unique strengths. The company’s work in this field places it among the leading tier. Professor Sun has many years of experience in PDC technology research, and we believe that under his leadership, the company will achieve steady and rapid development, enabling this technology to better benefit patients with cancer and autoimmune diseases.”

Xiantong Capital is one of the earliest globally operating, specialized biomedical venture capital firms in China founded by industry professionals. Focusing on the life sciences sector, it holds a leading professional advantage and possesses extensive project resources within the biomedical investment industry. Xiantong Capital identifies technologically innovative, high-growth enterprises with significant commercial potential and capital value, having supported and cultivated a number of benchmark companies in niche sectors.

Xiantong maintains offices in Shenzhen, Beijing, Suzhou, and Chicago. It has assembled an investment and advisory team comprising industry experts, scientists, and investors from the life sciences sector, and manages and operates a series of RMB and USD-denominated funds.

“Insight into the future, discovery of value, and turning stone into gold” are the core values of Xiantong Capital. Through years of focused and professional dedication in the fields of biomedicine and pharmaceuticals, the companies invested in by Xiantong Capital have gradually become leaders in their respective sectors.